SG11202107606VA - Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy - Google Patents

Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Info

Publication number
SG11202107606VA
SG11202107606VA SG11202107606VA SG11202107606VA SG11202107606VA SG 11202107606V A SG11202107606V A SG 11202107606VA SG 11202107606V A SG11202107606V A SG 11202107606VA SG 11202107606V A SG11202107606V A SG 11202107606VA SG 11202107606V A SG11202107606V A SG 11202107606VA
Authority
SG
Singapore
Prior art keywords
polypeptides
therapy
interleukin
mutated
mutated interleukin
Prior art date
Application number
SG11202107606VA
Inventor
Carole Guillonneau
Ignacio Anegon
Erwan Mortier
Agnès Quemener
Original Assignee
Inst Nat Sante Rech Med
Univ Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Nantes filed Critical Inst Nat Sante Rech Med
Publication of SG11202107606VA publication Critical patent/SG11202107606VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2334—Interleukin-34 (IL-34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11202107606VA 2019-01-15 2020-01-15 Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy SG11202107606VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305046 2019-01-15
PCT/EP2020/050920 WO2020148338A1 (en) 2019-01-15 2020-01-15 Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Publications (1)

Publication Number Publication Date
SG11202107606VA true SG11202107606VA (en) 2021-08-30

Family

ID=65228484

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107606VA SG11202107606VA (en) 2019-01-15 2020-01-15 Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Country Status (12)

Country Link
US (1) US20220098264A1 (en)
EP (1) EP3911670A1 (en)
JP (1) JP2022517029A (en)
KR (1) KR20210121077A (en)
CN (1) CN113508129A (en)
AU (1) AU2020208909A1 (en)
BR (1) BR112021013944A8 (en)
CA (1) CA3126741A1 (en)
IL (1) IL284868A (en)
MX (1) MX2021008525A (en)
SG (1) SG11202107606VA (en)
WO (1) WO2020148338A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819614B (en) * 2022-06-21 2024-02-23 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells based on IL34
WO2023246908A1 (en) * 2022-06-21 2023-12-28 四川大学华西医院 Preparation and use of chimeric antigen receptor immune cell targeting csf1r

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR520E (en) 1901-11-13 1903-01-26 Bermont Victor Etienne Industrial process for the direct extraction of zinc contained in oxidized ores, and more specifically in smithsonite (znco3) and scale (h2zn2sio5)
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DK0465529T3 (en) 1989-03-21 1998-10-05 Vical Inc Expression of exogenous polynucleotide sequences in a vertebrate
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DK1589107T3 (en) 1992-08-21 2010-04-26 Univ Bruxelles Immunuglobulins without light chains
WO1994019478A1 (en) 1993-02-22 1994-09-01 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (en) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition for the production of therapeutic products in vivo.
WO1995028494A1 (en) 1994-04-15 1995-10-26 Targeted Genetics Corporation Gene delivery fusion proteins
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP2112166B1 (en) 1998-12-23 2018-11-21 Pfizer Inc. Human monoclonal antibodies to ctla-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DE60033530T2 (en) 1999-08-24 2007-10-31 Medarex Inc. HUMAN ANTIBODIES TO CTLA-4 AND THEIR USES
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
MY137552A (en) 2000-07-03 2009-02-27 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2003032949A1 (en) 2001-10-19 2003-04-24 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
ES2744275T3 (en) 2002-10-17 2020-02-24 Genmab As Human monoclonal antibodies against CD20 for use in the treatment of multiple sclerosis
MXPA05006828A (en) 2002-12-23 2005-09-08 Wyeth Corp Antibodies against pd-1 and uses therefor.
WO2006012451A2 (en) * 2004-07-22 2006-02-02 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
SI2161336T1 (en) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
BRPI0613361A2 (en) 2005-07-01 2011-01-04 Medarex Inc isolated human monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, method for modulating an immune response in an individual, method for inhibiting tumor cell growth in an individual, method for treating an infectious disease in a subject, a method for enhancing an immune response to an antigen in a subject, a method for treating or preventing an inflammatory disease in a subject, and a method for preparing the anti-pd-11 antibody
HRP20131196T4 (en) 2005-12-20 2022-06-10 Bristol-Myers Squibb Company Stable protein formulations
CN104548091A (en) 2008-02-11 2015-04-29 治疗科技公司 Monoclonal antibodies for tumor treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
ES2545609T3 (en) 2008-08-25 2015-09-14 Amplimmune, Inc. PD-1 antagonist compositions and methods of use
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
KR20210060670A (en) 2008-12-09 2021-05-26 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
ES2571235T3 (en) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
BR122021025338B1 (en) 2009-11-24 2023-03-14 Medimmune Limited ISOLATED ANTIBODY OR BINDING FRAGMENT THEREOF AGAINST B7-H1, PHARMACEUTICAL COMPOSITION AND ITS USES
PL2581113T3 (en) 2010-06-11 2018-11-30 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
HUE051954T2 (en) 2011-11-28 2021-03-29 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
JP6313416B2 (en) 2013-03-15 2018-04-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ IDO inhibitor
CA2922607C (en) 2013-09-06 2022-08-30 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
EP3385257A1 (en) 2013-09-06 2018-10-10 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
JP6769948B2 (en) * 2014-07-17 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル An isolated interleukin-34 polypeptide for use in the prevention of transplant rejection and the treatment of autoimmune diseases
CN106084030B (en) * 2016-04-25 2019-11-08 北京大学 A method of improving interleukins IL-34 thermal stability

Also Published As

Publication number Publication date
CN113508129A (en) 2021-10-15
CA3126741A1 (en) 2020-07-23
BR112021013944A2 (en) 2021-11-21
US20220098264A1 (en) 2022-03-31
IL284868A (en) 2021-08-31
WO2020148338A1 (en) 2020-07-23
MX2021008525A (en) 2021-11-12
BR112021013944A8 (en) 2021-12-21
AU2020208909A1 (en) 2021-07-29
EP3911670A1 (en) 2021-11-24
KR20210121077A (en) 2021-10-07
JP2022517029A (en) 2022-03-03

Similar Documents

Publication Publication Date Title
IL265489B (en) Recombinant binding proteins and their use
IL287781A (en) Clec12a-binding polypeptides and uses thereof
IL304469A (en) Reprogrammable tnpb polypeptides and use thereof
IL284868A (en) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
IL287782A (en) Cd33-binding polypeptides and uses thereof
IL283241A (en) Engineered robust high tm-phytase clade polypeptides and fragments thereof
SG11202101173TA (en) Ox40-binding polypeptides and uses thereof
IL261397A (en) Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
SG10201912408WA (en) Chimeric polypeptides and methods of altering their localisation in the cell membrane
EP3813861A4 (en) Heparin-associated polypeptides and uses thereof
GB201819200D0 (en) Polypeptide and uses thereof
EP4081241A4 (en) Regenerative polypeptides and uses thereof
GB202201003D0 (en) Fusion polypeptide and use thereof
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
GB202201001D0 (en) Polypeptide and use thereof
GB202201004D0 (en) Reconbinant fusion polypeptide and use thereof
EP3684796A4 (en) Succinate-regulating polypeptides and use thereof
EP3425054C0 (en) Mutant cytochrome protein and use thereof
EP4103586A4 (en) Polypeptides and their use
EP3611181A4 (en) Atp1a1-targeting polypeptide and use
IL278009B1 (en) 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy
IL275241A (en) Engineered o-glycosylation in recombinant polypeptides and uses thereof
GB2582571B (en) Peptides and use thereof
EP3544622A4 (en) Peptidomimetics and their use in therapy
IL309885A (en) Alpha-sheet polypeptides and their use